Introduction
Colon cancer is one of the most commonly diagnosed cancers among both men and women in the United States. 1 Presently, colon cancer is staged according to a system designed by the American Joint Committee on Cancer (AJCC) that defines the prognosis in a clear manner and is thus used for clinical treatment decisions. The AJCC staging system differentiated patients on the basis of the invasion extent of primary tumor (T-stage), lymph node status (N-stage), and distant spread (M-stage). However, the TNM staging system is not perfect for the prognostic prediction and clinical management of colon cancer. The AJCC issued a request for proposals to develop staging methods based on other available information beyond the classical TNM staging.
The present study focused on improving the AJCC TNM staging system. In 1990, Kune et al 3 suggested that older patients with colon cancer might have worse survival compared with younger patients. In 1984, Phillips et al 4 reported that the tumor grade was an independent prognostic factor in large bowel cancer. Also, Kornprat et al 5 analyzed 359 patients with colon cancer and reported that the tumor size was significantly associated with progression-free and cancerspecific survival (CSS) and negatively impacted survival.
Moreover, many subsequent studies revealed that age at diagnosis, [6] [7] [8] [9] tumor grade, 10, 11 and tumor size 12, 13 had a strong correlation with the prognosis of colon cancer. Yet most of them focus on the prognostic significance of one single factor and no study attempt to combine the three factors together for improved prognostic prediction. Therefore, this study proposed a novel prognostic score based on 3 patient and tumor characteristics, consequently obtaining the P-stage from the prognostic score. The present study analyzed the combined value of P-stage and the TNM staging system in predicting the prognosis and clinical management.
Patients and methods

Study design and data source
The Surveillance, Epidemiology, and End Results (SEER) database is an authoritative source of information on cancer incidence and survival in the United States. This database provides a comprehensive source of population-based information including all newly diagnosed cancer cases among people residing in areas participating in the SEER program and covering approximately 28% of the US population.
As shown in Figure 1 , data were obtained for 185,617 patients with a diagnosis of malignant colorectal cancer between January 1, 2010, and December 31, 2014, from the SEER program of the National Cancer Institute. Among these patients, 68,945 patients who satisfied the following inclusion criteria were identified: colon cancer, age, grade, tumor size, the seventh edition of TNM staging available, and 1 malignant primary tumor only. Patients with T0-or Tis-stage were excluded for an accurate staging. Patients with nonadenocarcinoma histology or unknown surgery status were also excluded. Finally, the target population included 
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P-TNM staging system for colon cancer 56,800 colon cancer patients with diagnosis based on the seventh edition of TNM stage and 3 specific prognostic factors (age at diagnosis, tumor grade, and tumor size) available.
P-stage: risk-stratification
Patients were stratified based on a prognostic score incorporating 3 patient and tumor characteristics (age at diagnosis, tumor grade, and tumor size) that have been reported to influence the survival of colon cancer patients. [3] [4] [5] [6] [7] [8] [10] [11] [12] [13] As can be seen in Figure 2 , we calculated the total score with 0, 1, 2, and 3 points each given for age (≤49, >49-64, >64-79, >79 years), grade (well differentiated or grade I; moderately differentiated or grade II; poorly differentiated or grade III; undifferentiated, anaplastic or grade IV), and tumor size (≤2, >2-4, <4-6, >6 cm). The total scores ranged from 0 to 9, then a comprehensive prognostic score based on the 3 prognostic factors was obtained, with a score of 0 having the best prognosis and those with a score of 9 having the worst prognosis. These cut points were based on the prior cohort studies concerning the prognostic factors of age at diagnosis, 7 tumor grade, 11 and tumor size. 13 Finally, we got the P-stage of each patient according to the prognostic score -score 0-4 was assigned to P0-stage and score 5-9 was assigned to P1-stage.
Statistical analyses
Several Cox proportional hazards models were built to identify independent prognostic variables at a median survival time of 20 months (ranged 0-59 months). All the hazard ratios (HRs) are shown with 95% confidence interval (CI). The endpoint used for comparison in the present study was 59-month CSS based on selected patients with colon cancer because the longest follow-up time was 59 months, not >5 years. Variables that showed prognostic significance (log-rank, P<0.20) in the univariate analysis were included in the multivariate analysis of the selected patients. Moreover, the variables, including P-stage, TNM stage, tumor location, surgery status, histology, race, and year of diagnosis, were included in the multivariate analyses using Cox proportional hazards models. The TNM staging used in this study was the seventh edition of the AJCC cancer staging system, the newest TNM stage that could be obtained from the SEER database. This study also designed a variable called the "N-P stage," combining the N-stage (N0-, N1-, N2a-, and N2b-stage) and the P-stage (P0 and P1, based on the prognostic score), to compare the interaction between these 2 stages in patients with nonmetastatic colon cancer. The Kaplan-Meier survival curves were used to evaluate the prognostic prediction of different factors and the log-rank tests to assess the statistical significance. A P-value <0.05 was considered statistically significant. A statistical analysis was performed using the SPSS version 22 (IBM Corporation, Armonk, NY, USA).
Ethics statement
The study was approved by the Ethical Committee and Institutional Review Board of the Fudan University Shanghai Cancer Center. The data did not include the use of human subjects or personal identifying information, and so no informed consent was required for this study.
Results
P-stage was strongly associated with the survival of colon cancer
The median follow-up time for the overall cohort was 20 months. At the end of the follow-up time, 8,841 (15.6%) patients died of colon cancer. Table S1 demonstrates that higher grade, larger tumor size, and older age are associated with poorer survival, which was consistent with a prior study.
14 A multivariable analysis was conducted to identify the variables independently associated with CSS in the overall cohort, and it was found that the P1-stage was independently associated with 59-month CSS of 56,800 patients with colon cancer and had a 98.1% increased risk of cancer-specific mortality (HR =1.981, 95% CI =1.891-2.076, P<0.001; 
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Liu et al showed a 131.5% increased risk of cancer-specific mortality in patients with nonmetastatic colon cancer (higher than that in the overall cohort), indicating that the prognostic prediction efficacy of P-stage improved in patients with AJCC stage I-III colon cancer.
Prognostic prediction of P-TNM stage: combination of P-stage and AJCC TNM staging system
The survival curves of all P-TNM stage (AJCC TNM staging system combined with P-stage) were used to analyze the prognostic prediction of the P-TNM stage in the overall cohort (n=56,800; Figure 3A -C). As expected, all P0-stage patients showed a statistically significant increase in the 59-month CSS compared with the P1-stage patients (P<0.001) in the respective AJCC TNM stages. Moreover, as Figure 3A -C also shows, an increased or similar 59-month CSS of stage P0-TNM patients compared with stage P1-TNM patients with higher AJCC stages was observed. A decreased CSS was also found in stage I-P1 patients compared with stage IIIA-P0 or IIA-P0 patients (P<0.001), stage IIIA-P1 patients compared with stage IIA-P0 patients (P<0.001), stage IIB-P1 patients compared with stage IIIB-P0 or IIC-P0 patients (P<0.001), stage IIIB-P1 patients compared with stage IIC-P0 patients (P<0.001), and stage IIC-P1 patients compared with stage IIIC-P0 patients (P<0.001). Thus, a considerable overlap existed between the Kaplan-Meier survival curves of adjacent AJCC TNM stages. The Kaplan-Meier survival curves of stages I-P0, I-P1, II-P0, II-P1, III-P0, and III-P1 also showed that the P0-stage patients had a statistically significant increase in the 59-month CSS compared with the P1-stage patients (P<0.001) in the respective AJCC TNM stages ( Figure 3D ). It was thus easily found that stage III-P0 had no significant difference from stage IIIA-P1 ( Figure S1 ). Figure 4 shows that Kaplan-Meier survival curves of different TNM stages.
Multivariate Cox regression analyses were used to compare the HRs of each AJCC TNM stage and P-TNM stages. The 59-month CSS was also assigned to each P-TNM stage and TNM stage. Consistent with the Kaplan-Meier survival curves, stage P0-TNM patients showed increased 59-month CSS rates and decreased HRs compared with the respective stage migration indicated that the P-TNM stage had a more accurate prognostic prediction than the TNM stage after the combination with P-stage. Alternatively, the P1-stage had an upstage effect that P1 patients presented higher risk of cancer-specific mortality than those P0 patients with higher TNM stages in most patients with colon cancer. The prognostic prediction efficacy was even stronger in patients with nonmetastatic colon cancer.
Prognosis of N-stage combined with P-stage
Multivariate Cox regression analyses were also conducted in patients with nonmetastatic colon cancer to compare the HRs of each N-stage (N0, N1, N2a, and N2b) before and after the combination of P-stage, and the 59-month CSS was also assigned to each P-N stage and N-stage (Table 3 ). The stage 
Discussion
The AJCC TNM staging system is the most commonly used algorithm in the clinical practice of colon cancer. However, the TNM stage considers only the invasion extent of primary tumor (T-stage), lymph node status (N-stage), and distant spread (M-stage) without considering other factors that influence the prognosis of colon cancer. 15 This was not perfect for prognostic prediction, although several modifications in the past years had improved its predictive ability. AJCC had issued a request for staging methods based on other available information beyond the conventional TNM staging system. 2 Therefore, a more comprehensive staging that included other demographic and clinicopathologic variables known to impact the survival was urgently needed.
Previous studies showed that age at diagnosis, 3,6-9 tumor grade, 4,10,11 and tumor size 5,12,13 had a strong correlation with the prognosis of colon cancer. For example, Saha et al 13 found that the 5-year overall survival was 66%, 52%, 46%, and 41% in the subgroups with tumor sizes of 0-2, >2-4, >4-6, and >6 cm, respectively. In 2012, Patel et al 7 reported that the oldest age group (>80 years old) had a 238% increased overall mortality compared with the youngest age group (18-49 years). In 2011, Weiser et al 2 developed prognostic models (incorporating T-stage, N-stage, numbers of positive lymph nodes, numbers of total lymph nodes, age, gender, and tumor grade) that outperformed the current AJCC TNM staging system. Considering that HRs of male and female 
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P-TNM staging system for colon cancer patients with colon cancer were not significantly different (Table 1 ) and the numbers of positive lymph nodes and total lymph nodes had some overlap with the N-stage, these were not included in the P-TNM stage in this study. In the present large, representative, population-based study, the AJCC TNM staging system was extended to include patient-and tumor-related variables of age of diagnosis, tumor grade, and tumor size, which are rou-tinely available from the SEER database, and the 59-month CSS of each P-TNM stage, and thus a combination of the newly proposed P-stage and TNM stage was analyzed. The present study confirmed that all P1-stage patients had a statistically significant increase in mortality compared with the P0-stage patients with the same TNM stage. Also, the 98.1% increased HR in the overall cohort and 131.5% increased HR in the patients with nonmetastatic colon cancer also proved that the P1-stage greatly increased the 59-month cancer-specific mortality. The study also showed that several P1-TNM stages even exceeded the P0-TNM stages with higher AJCC TNM stages. The better prognosis of patients with several node-positive stages (stage IIIA-P0, IIIA-P1, or IIIB-P0) than that of several node-negative stages (stage IIC-P0, IIB-P0, IIA-P1, or IIA-P0) seemed to explain that a part of node-negative patients had a bad prognosis and that not all patients with node-positive status had a poor prognosis. 16, 17 Besides, this study showed that the P1-stage patients had a worse prognosis than the N1-, N2a-, and even N2b-stage patients, indicating that the P1-stage might be a more powerful predictor of worse prognosis compared with the node-positive status. Given the benefits of chemotherapy in node-positive patients, 18 ,19 the P1-stage in this study was of great significance in indicating the use of chemotherapy. Also, in the analyses of P-TNM stage, it could be seen that the stage I (T1-T2N0M0)-P1 had a worse prognosis than stage IIIA (T1-T2N1M0)-P0. Considering almost the same in the T-stage (T1-T2), the P1-stage was once again proved to be stronger than the N1-stage for indicating a poor prognosis. However, in the clinical treatment today, stage IIIA patients are treated with adjuvant chemotherapy, while stage I patients are not. 20 Therefore, this study took into account the possibility of under treatment in the TNM stage I colon cancer and overtreatment in the TNM stage IIIA colon cancer. Fortunately, the P-stage could distinguish well between stages I-P0 and I-P1 in the TNM stage I, and extremely well between stages IIIA-P0 and IIIA-P1 in the TNM stage IIIA (which also seemed to account for the better prognosis of TNM stage IIIA than stage IIIA). 2, 21 Moreover, toxicity and adverse events caused by adjuvant chemotherapy could result in significant patient morbidity. 22 The present study suggested that the recommendation of reduced chemotherapy in stage IIIA-P0 deserves further investigation and prospective studies with the incorporation of the newly proposed P-stage. Therefore, this study strongly supported adding the P-stage into the conventional TNM staging system to generate a more refined, risk-adapted stage and thus guide the clinical treatment of colon cancer.
The adjuvant chemotherapy of TNM stage II has long been studied. At present, it has been widely accepted that patients with TNM stage II with any of high-risk factors, such as T4-stage, obstruction, perforation, poorly differentiated histology, <12 lymph nodes, presence of lymphovascular or perineural invasion, or positive margins, 11, [23] [24] [25] [26] might be considered as candidates for adjuvant chemotherapy. In 2004, the American Society of Clinical Oncology recommended the use of adjuvant chemotherapy, especially for patients with high-risk TNM stage II colon cancer, despite adequate indirect evidence of benefit. 18 The guidelines published by the European Society for Medical Oncology also recommend adjuvant chemotherapy for the high-risk stage II colon cancer despite insufficient scientific evidence supporting the effectiveness of adjuvant chemotherapy in this group of patients. 27 However, in 2011, O'Connor et al 24 reported that patients with stage II colon cancer with any high-risk factors (including obstruction, perforation, emergent admission, T4-stage, resection of fewer than 12 lymph nodes, and poor histology) did not get substantial survival benefit from adjuvant chemotherapy. In 2016, Verhoeff et al 28 showed similar results after analyzing 4,940 patients with high-risk stage II colon cancer (pT4, poor/undifferentiated grade, emergency surgery, and/or <10 evaluated lymph nodes). Given that high risks did not include the tumor size and age at diagnosis, this study considered that the P-stage might improve this situation.
Moreover, 1 distinct advantage of the simple and convenient P-stage was that the 3 prognostic factors (including age at diagnosis, tumor grade, and tumor size) were readily available and could even be specified preoperatively (tumor size known by colonoscopy, and then the colonoscopy biopsy to specify the tumor grade). After combining with the preoperative TNM stage, the P-TNM stage could be obtained, which is a more refined stage for better predicting the prognosis and guiding preoperative treatment for patients with colon cancer.
This study still had several limitations. First, the P-TNM stage did not take into account other prognostic factors, including the microsatellite instability status, treatment, carcinoembryonic antigen level, and so on. This could independently affect the survival, 19, 29, 30 indicating that the P-TNM stage is not perfect and needs further improvement. Anatomical staging might be less important compared with the treatment factors (patients who received adjuvant therapy and the specific regimens of the therapy). Whether the stage IIIA-P0 had a good prognosis on account of biological characteristics (discriminated by P-stage) or treatment effect (adjuvant therapy) still remains unknown. However, the P1-stage might have a worse prognosis compared with the N2a-and N2b-stage in node-positive patients, and this study still recommended less chemotherapy in the stage IIIA-P0 
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P-TNM staging system for colon cancer patients. Second, the overall cohort incorporated 56,800 patients from the SEER database; hence, the sample size still needs to be enlarged. The longest follow-up time was only 59 months, not exceeding 5 years. Besides, the analyses were merely based on retrospective data. Therefore, prospective clinical studies concerning P-stage need to be carried out for more sensitive prognosis prediction compared with N-stage and prognosis discrimination of each TNM stage.
Conclusion
The newly proposed P-stage, which is easily available even before performing operation on patients, explains the lack of clear ranking by stage in predicting outcomes using the conventional TNM stage. The present study strongly supported the incorporation of P-stage into the AJCC TNM stage (ie, the P-TNM stage) for a better approach to prognostication and, thus, more individualized risk-adaptive therapies. 
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